Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Q Wu

Showing results (31-40 of 201) with videos related to

Pageof 21
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|June 15, 2018
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatmentRajeev Ayyagari, Jipan Xie, David Cheng, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 1, 2007
Productivity costs associated with cardiometabolic risk factor clusters in the United StatesPatrick W Sullivan, Vahram Ghushchyan, Holly R Wyatt, et al.
Obesity (Silver Spring, Md.)|February 15, 2007
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.SPatrick W Sullivan, Vahram Ghushchyan, Holly R Wyatt, et al.
Journal of Medical Economics|April 20, 2011
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysisAndrew P Yu, Hongbo Yang, Eric Q Wu, et al.
Current Medical Research and Opinion|June 29, 2012
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world settingAnnie Guérin, Lei Chen, Eric Q Wu, et al.
Clinical Therapeutics|April 6, 2016
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid ArthritisKeith A Betts, Jenny Griffith, Arijit Ganguli, et al.
BMC Pulmonary Medicine|December 31, 2015
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosisWilliam M Reichmann, Yanni F Yu, Dendy Macaulay, et al.
Journal of Women'S Health (2002)|May 5, 2017
Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or LaparoscopyAhmed M Soliman, Ella Xiaoyan Du, Hongbo Yang, et al.
Journal of Health Economics and Outcomes Research|August 8, 2022
Erratum: Author Correction: Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United StatesFeng Lin, Winghan J Kwong, Sherry Shi, et al.
Pharmacoeconomics|February 1, 2006
Interstitial Cystitis: Cost, treatment and co-morbidities in an employed populationEric Q Wu, Howard Birnbaum, Milena Mareva, et al.
Pageof 21

Showing results (31-40 of 201) with videos related to

Sort By:
Pageof 21
Journal of Clinical Hypertension (Greenwich, Conn.)|June 15, 2018
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatmentRajeev Ayyagari, Jipan Xie, David Cheng, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 1, 2007
Productivity costs associated with cardiometabolic risk factor clusters in the United StatesPatrick W Sullivan, Vahram Ghushchyan, Holly R Wyatt, et al.
Obesity (Silver Spring, Md.)|February 15, 2007
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.SPatrick W Sullivan, Vahram Ghushchyan, Holly R Wyatt, et al.
Journal of Medical Economics|April 20, 2011
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysisAndrew P Yu, Hongbo Yang, Eric Q Wu, et al.
Current Medical Research and Opinion|June 29, 2012
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world settingAnnie Guérin, Lei Chen, Eric Q Wu, et al.
Clinical Therapeutics|April 6, 2016
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid ArthritisKeith A Betts, Jenny Griffith, Arijit Ganguli, et al.
BMC Pulmonary Medicine|December 31, 2015
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosisWilliam M Reichmann, Yanni F Yu, Dendy Macaulay, et al.
Journal of Women'S Health (2002)|May 5, 2017
Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or LaparoscopyAhmed M Soliman, Ella Xiaoyan Du, Hongbo Yang, et al.
Journal of Health Economics and Outcomes Research|August 8, 2022
Erratum: Author Correction: Surgical Treatment Patterns, Healthcare Resource Utilization, and Economic Burden in Patients with Tenosynovial Giant Cell Tumor Who Underwent Joint Surgery in the United StatesFeng Lin, Winghan J Kwong, Sherry Shi, et al.
Pharmacoeconomics|February 1, 2006
Interstitial Cystitis: Cost, treatment and co-morbidities in an employed populationEric Q Wu, Howard Birnbaum, Milena Mareva, et al.
Pageof 21